These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2841880)

  • 21. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules.
    Tsai TF; Yu YX; Jia LL; Putvatana R; Zhang R; Wang S; Halstead SB
    J Infect Dis; 1998 Jan; 177(1):221-3. PubMed ID: 9419193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
    Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
    Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.
    Sricharoenchai S; Lapphra K; Chuenkitmongkol S; Phongsamart W; Bouckenooghe A; Wittawatmongkol O; Rungmaitree S; Chokephaibulkit K
    Pediatr Infect Dis J; 2017 Feb; 36(2):e45-e47. PubMed ID: 27846060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China.
    Liu X; Yu Y; Li M; Liang G; Wang H; Jia L; Dong G
    Vaccine; 2011 Mar; 29(11):2127-30. PubMed ID: 21237278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.
    Wang R; Xie L; Gao N; Fan D; Chen H; Wang P; Zhou H; An J
    Virol Sin; 2019 Jun; 34(3):243-252. PubMed ID: 30911897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of wild-type and vaccine strains of Japanese encephalitis virus and the effect of haplotype restriction on murine immune responses.
    Wills MR; Singh BK; Debnath NC; Barrett AD
    Vaccine; 1993; 11(7):761-6. PubMed ID: 8342323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response in mice infected with the attenuated Japanese encephalitis vaccine strain SA14-14-2.
    Lee T; Komiya T; Watanabe K; Aizawa C; Hashimoto H
    Acta Virol; 1995 Jun; 39(3):161-4. PubMed ID: 8578998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is a booster dose necessary in children after immunization with live attenuated Japanese encephalitis vaccine?
    Choi UY; Lee SY; Kim KH; Kim DS; Choi KM; Cha SH; Kang JH
    J Trop Pediatr; 2013 Oct; 59(5):423-5. PubMed ID: 23764540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses.
    Jia L; Wang Z; Yu Y
    Chin Med J (Engl); 2003 Jun; 116(6):941-3. PubMed ID: 12877812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines.
    Nimmannitya S; Hutamai S; Kalayanarooj S; Rojanasuphot S
    Southeast Asian J Trop Med Public Health; 1995 Dec; 26(4):689-93. PubMed ID: 9139377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel amino acid site closely associated with the neurovirulence of live, attenuated Japanese encephalitis vaccine (SA14-14-2 strain).
    Yang H; Fan F; Liu L; Liu J; Sun Y; Xie A; Shi X; Liu L; Yu Y; Li Y; Ge Y; Zeng X; Yang H
    Vaccine; 2020 Mar; 38(11):2636-2642. PubMed ID: 32044162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
    Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
    Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
    Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A
    Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of Japanese encephalitis vaccines.
    Hu YL; Lee PI
    Hum Vaccin Immunother; 2021 Nov; 17(11):4259-4264. PubMed ID: 34613870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus.
    Okuno Y; Okamoto Y; Yamada A; Baba K; Yabuuchi H
    Vaccine; 1987 Jun; 5(2):128-32. PubMed ID: 3037813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study.
    Hennessy S; Liu Z; Tsai TF; Strom BL; Wan CM; Liu HL; Wu TX; Yu HJ; Liu QM; Karabatsos N; Bilker WB; Halstead SB
    Lancet; 1996 Jun; 347(9015):1583-6. PubMed ID: 8667866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibody rather than cellular immune response is maintained for nearly 20 years among Japanese encephalitis SA14-14-2 vaccinees in an endemic setting.
    Wang R; Fan D; Wang L; Li Y; Zhou H; Gao N; An J
    Infect Genet Evol; 2020 Nov; 85():104476. PubMed ID: 32736041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of cytoxan on immune response of Japanese encephalitis virus killed and live vaccines].
    Fang QA; Chen BQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Oct; 11(5):317-21. PubMed ID: 2561510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases.
    Yamada A; Imanishi J; Juang RF; Fukunaga T; Okuno Y; Tadano M; Fukai K; Baba K; Yabuuchi H
    Vaccine; 1986 Mar; 4(1):32-4. PubMed ID: 3008460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
    Markoff L
    Vaccine; 2000 May; 18 Suppl 2():26-32. PubMed ID: 10821970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.